Adaptimmune Therapeutics PLC — Director's Dealing 2019

Jul 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2019-07-02

Reporting Person: MOTT DAVID M (Director, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-07-02	Option to purchase Ordinary Shares	$0.61	A	350947	Acquired	2029-07-02	Ordinary Shares (350947)	Direct

Footnotes

F1: The exercise price was converted from GBP0.48 based on an exchange rate of $U.S. 1.2638 to GBP1.00. The actual exercise price will be the pounds sterling amount.